Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

February 28, 2030

Study Completion Date

June 30, 2030

Conditions
Kidney StoneNephrolithiasisDietary Exposure
Interventions
DRUG

Empagliflozin 25 MG

Once daily per os for 3 years

DRUG

Placebo

Once daily per os for 3 years

BEHAVIORAL

Personalized dietary counseling

Personalized dietary counseling based on repeat 24-hr urine collections and dietary assessments for 3 years

BEHAVIORAL

Generic dietary counseling

Generic dietary counseling based on current guidelines without 24-hr urine collection results and without specific dietary assessments for 3 years

Trial Locations (21)

1011

Lausanne University Hospital (CHUV), Lausanne

1211

University Hospital Geneva (HUG), Geneva

1708

Kantonsspital Fribourg, Fribourg

1950

Kantonsspital Sion, Sion

2000

Kantonsspital Neuchâtel, Neuchâtel

3010

Inselspital Bern, Bern

4031

University Hospital Basel, Basel

4500

Kantonsspital Solothurn, Solothurn

4600

Kantonsspital Olten, Olten

5001

Kantonsspital Aarau, Aarau

5404

Kantonsspital Baden, Baden

6016

Kantonsspital Luzern, Lucerne

6500

Regionalspital Bellinzona e Valli, Bellinzona

6900

Regionalspital Lugano, Lugano

7000

Kantonsspital Chur, Chur

8091

Universitätsspital Zürich, Zurich

9007

Kantonsspital St. Gallen, Sankt Gallen

10117

Charité University Medicine Berlin, Berlin

37134

Verona University Hospital, Verona

75020

Hôpital Tenon, Paris

80054

University Hospital Amiens-Picardie, Amiens

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER